Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and finished products. The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the … Read more

Exit mobile version